Infections in Patients with Cancer: Overview

  • Amar Safdar
  • Gerald Bodey
  • Donald Armstrong
Part of the Current Clinical Oncology book series (CCO)


Patients with neoplastic disease are often highly susceptible to severe infections. The following factors influence the types, severity, and response to therapy of these infections: (1) Changing epidemiology of infections; (2) cancer- and/or treatment-associated neutropenia; (3) acquired immune deficiency states such as cellular immune defect; (4) recent development of new-generation diagnostic tools including widely available DNA amplification tests; (5) effective intervention for infection prevention; (6) empiric or presumptive therapy during high-risk periods; (7) availability of new classes of highly active antimicrobial drugs; (8) strategies to promote hosts’ immune response; and (9) future measures. This introductory chapter intended for the reader to become familiar with the important historical milestones in the understanding and development in the field of infectious diseases in immunosuppressed patients with an underlying neoplasms and patients undergoing hematopoietic stem cell trans­plantation.


Cancer Infection Neutropenia Immune defects Diagnosis Therapy 


  1. 1.
    Dameshek W, Gunz F. Leukemia. 1st ed. New York: Grune & Stratten; 1958.Google Scholar
  2. 2.
    DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–53.PubMedGoogle Scholar
  3. 3.
    Gaydos LA, Freireich EJ, Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med. 1962;266:905–9.PubMedGoogle Scholar
  4. 4.
    Hersh EM, Bodey GP, Nies BA, et al. Causes of death in acute leukemia. A ten year study of 414 patients from 1954-1963. JAMA. 1965;193:105–9.PubMedGoogle Scholar
  5. 5.
    Armstrong D. Infections complicates of neoplastic diseases: diagnosis and management – part I. Clin Bull. 1976;6:135–41.PubMedGoogle Scholar
  6. 6.
    Armstrong D. Infections complicates of neoplastic diseases: diagnosis and management – part II. Clin Bull. 1977;7:13–20.PubMedGoogle Scholar
  7. 7.
    Armstrong D. Infections in patients with neoplastic disease. In: Verhoef J et al., editors. Infections in the immunocompromised host – Pathogenesis, prevention and therapy. New York: Elsevier/North Holland; 1980. p. 129–58.Google Scholar
  8. 8.
    Brown AE, Armstrong D, editors. Controversies in the management of infectious complications of neoplastic disease. New York: Yorke Medical Books; 1985. p. 1–424.Google Scholar
  9. 9.
    Armstrong D, Brown AE. Controversies in the management of infectious complications of neoplastic disease. Rev Infect Dis. 1993;17 Suppl 2:317–551.Google Scholar
  10. 10.
    Brown AE. White MH. Controversies in the management of immunocompromised patients. Clin Infect Dis. 1993;17 Suppl 2:317–551.Google Scholar
  11. 11.
    Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin. 2001;17:531–70.PubMedGoogle Scholar
  12. 12.
    Boggs DR, Frei III E. Clinical studies of fever and infection in cancer. Cancer. 1960;6:1240–53.Google Scholar
  13. 13.
    Raab SO, Hoeprich PD, Wintrob MM, et al. The clinical significance of fever in acute leukemia. Blood. 1960;16:1609–28.PubMedGoogle Scholar
  14. 14.
    Bodey GP, Hersh EM. The problem of infection in children with malignant disease. In: Neoplasia in childhood. Proceedings of the 12th Annual Clinical Conference at the University of Texas M. D. Anderson Hospital and Tumor Institute at Houston. Chicago, IL, Year Book Medical; 1969. p. 135–54.Google Scholar
  15. 15.
    Bodey GP, Buckley M, Sathe YS, et al. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–40.PubMedGoogle Scholar
  16. 16.
    Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med. 1975;135:715–9.PubMedGoogle Scholar
  17. 17.
    Bodey GP, Powell Jr RD, Hersh EM, et al. Pulmonary complications of acute leukemia. Cancer. 1966;19:781–93.PubMedGoogle Scholar
  18. 18.
    Valdivieso M, Gil-Extremera B, Zornoza J, et al. Gram-negative bacillary pneumonia in the compromised host. Medicine. 1977;56:241–54.PubMedGoogle Scholar
  19. 19.
    Lawson RD, Gentry LO, Bodey GP, et al. Randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies. Am J Med Sci. 1984;287:16–23.PubMedGoogle Scholar
  20. 20.
    Morse EE, Freireich EJ, Carbone PP, et al. The transfusion of leukocytes from donors with chronic myelogenous leukemia to patients with leukopenia. Transfusion. 1966;6:183–92.Google Scholar
  21. 21.
    Hester JP, Kellogg RM, Mulzet AP, et al. Principles of blood separation and component extraction in a disposable continuous-flow single-state channel. Blood. 1979;54:254–68.PubMedGoogle Scholar
  22. 22.
    Vallejos C, McCredie KB, Bodey GP, et al. White blood cell transfusions for control of infections in neutropenic patients. Transfusion. 1975;15:28–33.PubMedGoogle Scholar
  23. 23.
    Wright DG, Robichaud KJ, Pizzo PA, et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 1981;304:1185–9.PubMedGoogle Scholar
  24. 24.
    Winston DJ, Ho WG, Young LS, et al. Prophylactic granulocyte transfusions during human bone marrow transplantation. Am J Med. 1980;68:893–7.PubMedGoogle Scholar
  25. 25.
    Bishton M, Chopra R. The role of granulocyte transfusions in neurtropenic patients. Br J Haematol. 2004;127:501–8.PubMedGoogle Scholar
  26. 26.
    Anderlini P, Champlin RE. Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges. Blood. 2008;111:1767–72.PubMedGoogle Scholar
  27. 27.
    Bodey GP, Hart JS, Freireich EJ, Frei III E. Studies of a patient isolator unit and prophylactic antibiotics in cancer chemotherapy. Cancer. 1968;22:1018–26.PubMedGoogle Scholar
  28. 28.
    Bodey GP, Rosenbaum B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine. 1974;53:209–28.PubMedGoogle Scholar
  29. 29.
    Bodey GP, Rodriguez V. Infections in cancer patients on a protected environment - prophylactic antibiotic program. Am J Med. 1975;59:497–504.PubMedGoogle Scholar
  30. 30.
    Bodey GP, Gehan EA, Freireich EJ, Frei III E. Protected environment-prophylactic antibiotic program in the chemotherapy of acute leukemia. Am J Med Sci. 1971;252:138–51.Google Scholar
  31. 31.
    Bodey GP. Laminar air flow unit for patients undergoing cancer chemotherapy. In: Mirand EA, Back N, editors. Germ-Free Biology. New York, NY: Plenum Press; l969. p. 19–26.Google Scholar
  32. 32.
    Bodey GP, Rodriguez V, Murphy WK, Burgess MA, Benjamin RS. Protected environment-prophylactic antibiotic program for malignant sarcomas: Randomized trial during remission induction chemotherapy. Cancer. 1981;47:2422–9.PubMedGoogle Scholar
  33. 33.
    Bodey GP. Epidemiological studies of Pseudomonas speices in patients with leukmeia. Am J Med Sci. 1970;260:82–6.PubMedGoogle Scholar
  34. 34.
    Schimpff SC, Young VM, Greene WH, et al. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med. 1972;77:707–14.PubMedGoogle Scholar
  35. 35.
    Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297:1419–26.PubMedGoogle Scholar
  36. 36.
    Minamoto GY, Gold JWM, Scheinberg DA, et al. Infection with human T-cell leukemia virus type 1 in patients with leukemia. N Engl J Med. 1988;318:219–22.PubMedGoogle Scholar
  37. 37.
    Whitecar Jr JP, Bodey GP, Luna M. Pseudomonas bacteremia in cancer patients. Am J Med Sci. 1970;260:216–23.Google Scholar
  38. 38.
    Schimpff SC, Greene WH, Young VM, et al. Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. J Infect Dis. 1974;130(Suppl):24–31.Google Scholar
  39. 39.
    Tapper ML, Armstrong D. Bactermeia due to Pseudomonas aeruginosa complicating neoplastic disease. A progress report. J Infect Dis. 1974;130 Suppl:14–23.Google Scholar
  40. 40.
    Bodey GP, Whitecar Jr JP, Middleman E, et al. Carbenicillin therapy of Pseudomonas infections. JAMA. 1971;218:62–6.PubMedGoogle Scholar
  41. 41.
    Middleman EA, Watanabe A, Kaizer H, Bodey GP. Antibiotic combinations for infections in neutropenic patients. Evaluation of carbenicillin plus either cephalothin or kanamycin. Cancer. 1972;30:573–9.PubMedGoogle Scholar
  42. 42.
    Aisenberg G, Rolston KV, Dickey BF, Kontoyiannis DP, Raad II, Safdar A. Stenotrophomonas maltophilia pneumonia in cancer patients without traditional risk factors for infection, 1997–2004. Eur J Clin Microbiol Infect Dis. 2007;26:13–20.PubMedGoogle Scholar
  43. 43.
    Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45:1602–9.PubMedGoogle Scholar
  44. 44.
    Sidjabat HE, Silveira FP, Potoski BA, et al. Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis. 2009;49:1736–8.PubMedGoogle Scholar
  45. 45.
    Louria DB, Hensle T, Armstrong D, et al. Listeriosis complicating malignant disease: a new association. Ann Intern Med. 1967;67:261–81.Google Scholar
  46. 46.
    Safdar A, Armstrong D. Listeriosis in patients at a comprehensive cancer center, 1955–1997. Clin Infect Dis. 2003;37:359–64.PubMedGoogle Scholar
  47. 47.
    Armstrong D, Kiehn T, Boone N, et al. Mycobacterium haemophilum infections – New York City metropolitan area, 1990–1991. MMWR Morb Mortal Wkly Rep. 1991;40:636–43.Google Scholar
  48. 48.
    Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer. 1974;33:850–8.PubMedGoogle Scholar
  49. 49.
    Bodey GP, Middleman E, Umsawasdi T, et al. Infections in cancer patients – results with gentamicin sulfate therapy. Cancer. 1972;29:1697–701.PubMedGoogle Scholar
  50. 50.
    Klasterskly J, Vamecq G, Cappel R, et al. Effects of the combination of gentamicin and carbenicillin on the bactericidal activity of serum. J Infect Dis. 1972;125:183–6.Google Scholar
  51. 51.
    Hughes WT, Armstrong D, Bodey GP, et al. From the working committee, Infectious Diseases Society of America: guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis. 1990;161:381–96.PubMedGoogle Scholar
  52. 52.
    Viscoli C, for the European Organization for the Research and Treatment of Cancer. Management of infection in cancer patients: studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer. 2002;38:82–7.Google Scholar
  53. 53.
    Pizzo PA, Armstrong D, Bodey G, et al. From the Immunocompromised Host Society: the design, analysis, and reporting of the clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis. 1990;161:397–401.Google Scholar
  54. 54.
    De La Rosa GR, Jacobson KL, Rolston KV, Raad II, Kontoyiannis DP, Safdar A. Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990-2000. Clin Microbiol Infect. 2004;10:749–52.Google Scholar
  55. 55.
    Aisenberg GM, Jacobson K, Chemaly RF, Rolston KV, Raad II, Safdar A. Extrapulmonary tuberculosis active infection misdiagnosed as cancer: Mycobacterium tuberculosis disease in patients at a Comprehensive Cancer Center (2001–2005). Cancer. 2005;104:2882–7.PubMedGoogle Scholar
  56. 56.
    Han XY, Tarrand JJ, Infante R, Jacobson KL, Truong M. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol. 2005;43:4407–12.PubMedGoogle Scholar
  57. 57.
    Safdar A, White DA, Stover D, Armstrong D, Murray HW. Profound interferon gamma deficiency in patients with chronic pulmonary nontuberculous mycobacteriosis. Am J Med. 2002;113:756–9.PubMedGoogle Scholar
  58. 58.
    Safdar A, Armstrong D, Murray HW. A novel defect in interferon-gamma secretion in patients with refractory nontuberculous pulmonary mycobacteriosis. Ann Intern Med. 2003;138:521.PubMedGoogle Scholar
  59. 59.
    Rolston KV, Jones PG, Fainstein V, Bodey GP. Pulmonary disease caused by rapidly growing mycobacteria in patients with cancer. Chest. 1985;87:503–6.PubMedGoogle Scholar
  60. 60.
    Jacobson K, Garcia R, Libshitz H, Whimbey E, Rolston K, Abi-Said D, et al. Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients. Eur J Clin Microbiol Infect Dis. 1998;17:615–21.PubMedGoogle Scholar
  61. 61.
    Han XY, Dé I, Jacobson KL. Rapidly growing mycobacteria: clinical and microbiologic studies of 115 cases. Am J Clin Pathol. 2007;128:612–21.PubMedGoogle Scholar
  62. 62.
    Ingram CW, Tanner DC, Durack DT, Kernodle Jr GW, Corey GR. Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis. 1993;16:463–71.PubMedGoogle Scholar
  63. 63.
    Bodey GP. Fungal infections complicating acute leukemia. J Chronic Dis. 1966;19:667–87.PubMedGoogle Scholar
  64. 64.
    Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41:634–53.PubMedGoogle Scholar
  65. 65.
    Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–60.PubMedGoogle Scholar
  66. 66.
    Singer C, Kaplan MH, Armstrong D. Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases. Am J Med. 1977;62:731–42.PubMedGoogle Scholar
  67. 67.
    Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D. Bacteremia and fungemia in patients with neoplastic disease. Am J Med. 1987;82:723–30.PubMedGoogle Scholar
  68. 68.
    Safdar A, Perlin DS, Armstrong D. Hematogenous infections due to Candida parapsilosis: changing trends in fungemic patients at a comprehensive cancer center during the last four decades. Diagn Microbiol Infect Dis. 2002;44:11–6.PubMedGoogle Scholar
  69. 69.
    Bodey GP, Luna M. Skin lesions associated with disseminated candidiasis. JAMA. 1974;229:1466–8.PubMedGoogle Scholar
  70. 70.
    Bodey GP, DeJongh D, Isassi A, Freireich EJ. Hypersplenism due to disseminated candidiasis in a patient with acute leukemia. Cancer. 1969;26:417–20.Google Scholar
  71. 71.
    Ferreira RP, Yu B, Niki Y, Armstrong D. Detection of Candida antigenuria in disseminated candidiasis by immunoblotting. J Clin Microbiol. 1990;28:1075–8.PubMedGoogle Scholar
  72. 72.
    Horn R, Wong B, Kiehn TE, Armstrong D. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Rev Infect Dis. 1985;7:646–55.PubMedGoogle Scholar
  73. 73.
    Wingard JR. The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. Leuk Lymphoma. 1992;8:353–9.PubMedGoogle Scholar
  74. 74.
    Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med. 1991;325:1274–7.PubMedGoogle Scholar
  75. 75.
    Safdar A, van Rhee F, Henslee-Downey JP, Singhal S, Mehta J. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant. 2001;28:873–8.PubMedGoogle Scholar
  76. 76.
    Greene RE, Schlamm HT, Oestmann JW, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373–9.PubMedGoogle Scholar
  77. 77.
    Maschmeyer G, Beinert T, Buchheidt D, et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer. 2009;45:2462–72.PubMedGoogle Scholar
  78. 78.
    Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39:797–802.PubMedGoogle Scholar
  79. 79.
    Fisher BD, Armstrong D. Cryptococcal interstitial pneumonia: value of antigen determination. N Engl J Med. 1977;97:1440–1.Google Scholar
  80. 80.
    White M, Cirrincione C, Blevins A, Armstrong D. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis. 1992;165:960–3.PubMedGoogle Scholar
  81. 81.
    Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KVI. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30:851–6.PubMedGoogle Scholar
  82. 82.
    Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126–33.PubMedGoogle Scholar
  83. 83.
    Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, et al. Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990;28:1616–22.PubMedGoogle Scholar
  84. 84.
    Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K. Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis. 2006;43:e39–41.PubMedGoogle Scholar
  85. 85.
    Bayramoglu G, Sonmez M, Tosun I, Aydin K, Aydin F. Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection. 2008;36:68–70.PubMedGoogle Scholar
  86. 86.
    Rieger C, Geiger S, Herold T, Nickenig C, Ostermann H. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis. 2007;26:843–5.PubMedGoogle Scholar
  87. 87.
    Torres HA, Raad II, Kontoyiannis DP. Infections caused by Fusarium species. J Chemother. 2003;15 Suppl 2:28–35.PubMedGoogle Scholar
  88. 88.
    Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant. 2006;38:327–37.PubMedGoogle Scholar
  89. 89.
    Seidel MG, Peters C, Wacker A, Northoff H, Moog R, Boehme A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008;42:679–84.PubMedGoogle Scholar
  90. 90.
    Safdar A, Rodriguez GH, Lichtiger B, Dickey BF, Kontoyiannis DP, Freireich EJ, et al. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions. Cancer. 2006;106:2664–71.PubMedGoogle Scholar
  91. 91.
    Safdar A, Rodriguez G, Ohmagari N, Kontoyiannis DP, Rolston KV, Raad II, et al. The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation. Cancer. 2005;103:731–9.PubMedGoogle Scholar
  92. 92.
    Safdar A, Rodriguez G, Rolston KV, O’Brien S, Khouri IF, Shpall EJ, et al. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;39:157–64.PubMedGoogle Scholar
  93. 93.
    Safdar A. Fungal cytoskeleton dysfunction or immune activation triggered by beta-glucan synthase inhibitors: potential mechanisms for the prolonged antifungal activity of echinocandins. Cancer. 2009;115:2812–5.PubMedGoogle Scholar
  94. 94.
    Armstrong D, Chmel H, Singer C, Tapper M, Rosen PP. Non-bacterial infections associated with neoplastic disease. Eur J Cancer. 1975;11 Suppl:79–94.Google Scholar
  95. 95.
    Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101:4195–200.PubMedGoogle Scholar
  96. 96.
    Meyers JD, Flournoy N, Thomas ED. Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant. J Infect Dis. 1980;142:816–24.PubMedGoogle Scholar
  97. 97.
    Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101:407–14.PubMedGoogle Scholar
  98. 98.
    Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med. 1991;325:1601–7.PubMedGoogle Scholar
  99. 99.
    Arthur RR, Shah KV, Baust SJ, Santos GW, Saral R. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med. 1986;315:230–4.PubMedGoogle Scholar
  100. 100.
    Kim YJ, Boeckh M, Englund JA. Community respiratory virus infections in immunocompromised patients: hematopoietic stem cell and solid organ transplant recipients, and individuals with human immunodeficiency virus infection. Semin Respir Crit Care Med. 2007;28:222–42.PubMedGoogle Scholar
  101. 101.
    Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006;85:278–87.Google Scholar
  102. 102.
    Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME, Martin PJ, et al. Airflow decline after myeloablative allogeneic hematopoietic cell transplantation: the role of community respiratory viruses. J Infect Dis. 2006;193:1619–25.PubMedGoogle Scholar
  103. 103.
    Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143:455–67.PubMedGoogle Scholar
  104. 104.
    Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant. 2008;41:707–8.PubMedGoogle Scholar
  105. 105.
    La Rosa AM, Champlin RE, Mirza N, Gajewski J, Giralt S, Rolston KV, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis. 2001;32:871–6.PubMedGoogle Scholar
  106. 106.
    Tapper ML, Armstrong D. Malaria complicating neoplastic disease. Arch Intern Med. 1976;136:807–10.PubMedGoogle Scholar
  107. 107.
    Grant IH, Gold JWM, Wittner M, et al. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med. 1989;111:849–51.PubMedGoogle Scholar
  108. 108.
    Gubernot DM, Lucey CT, Lee KC, Conley GB, Holness LG, Wise RP. Babesia infection through blood transfusions: reports received by the US Food and Drug Administration, 1997–2007. Clin Infect Dis. 2009;48:25–30.PubMedGoogle Scholar
  109. 109.
    Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine. 1976;55:259–68.PubMedGoogle Scholar
  110. 110.
    Williams N, Scott AD. Neutropenic colitis: a continuing surgical challenge. Br J Surg. 1997;84:1200–5.PubMedGoogle Scholar
  111. 111.
    Howell PB, Walters PE, Donowitz GR, Farr BM. Risk factors for infection of adult patients with cancer who have tunneled central venous catheters. Cancer. 1995;75:1367–75.PubMedGoogle Scholar
  112. 112.
    Rotstein C, Brock L, Roberts RS. The incidence of first Hickman catheter-related infection and predictors of catheter removal in cancer patients. Infect Control Hosp Epidemiol. 1995;16:451–8.PubMedGoogle Scholar
  113. 113.
    Raad I, Kassar R, Ghannam D, Chaftari AM, Hachem R, Jiang Y. Management of the catheter in documented catheter-related coagulase-negative staphylococcal bacteremia: remove or retain? Clin Infect Dis. 2009;49:1187–94.PubMedGoogle Scholar
  114. 114.
    Fux CA, Wilson S, Stoodley P. Detachment characteristics and oxacillin resistance of Staphyloccocus aureus biofilm emboli in an in vitro catheter infection model. J Bacteriol. 2004;186:4486–91.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Infectious Diseases, Infection Control, and Employee HealthThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations